Weave has repositioned itself as an "AI-powered patient communications" platform while delivering solid financial growth with 17% revenue expansion and improved cash generation.
The strategic pivot to emphasize AI capabilities suggests management is adapting to market trends and potentially commanding premium pricing in healthcare technology. However, the addition of M&A risk language and AI regulatory compliance concerns indicates management anticipates increased operational complexity. The 6.5% increase in outstanding shares suggests continued equity dilution that investors should monitor.
Weave demonstrated healthy operational momentum with revenue growing 17% to $239 million and gross profit expanding 18% to $172 million, while operating cash flow improved 24% to $17.5 million. The balance sheet strengthened with stockholders' equity rising 23% to $82.4 million and total assets growing 10% to $208 million, though current assets declined 13% while current liabilities increased 10%. Overall, the financial picture reflects a growing company with improving profitability metrics and cash generation, though working capital dynamics warrant attention.
Operating cash flow grew 24% — strong conversion of earnings to cash, healthy business fundamentals.
Equity base grew 23% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Revenue growing 17% — solid top-line momentum, watch margins for quality of growth.
Receivables grew 16.1% — monitor days sales outstanding for collection efficiency.
Current assets declined 13% — monitor working capital adequacy and short-term liquidity.
R&D investment increased 10.5% — signals commitment to future product development, though near-term margin impact.
Current liabilities rose 10.4% — increased short-term obligations, watch current ratio.
Asset base grew 10.1% — expansion through organic growth, acquisitions, or capital deployment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →